Two projects awarded under the 2024 "Subsidy scheme for promising care" in the Netherlands

In September 2024, the Dutch Healthcare Institute (Zorginstituut Nederland, ZIN) announced two projects that were awarded under round 9 of the subsidy scheme for promising care in 2024:

• Cold plasma therapy for a diabetic foot wound or a venous leg wound;
• Nasal drops with stem cells in newborns with brain damage.

The cold plasma therapy for diabetic foot or venous leg wound (COSMAS trial) project will start in November 2024 and last three years and eight months. After the project's completion, the research results will be submitted to the ZIN around July 2028 for a decision about inclusion in Basic Health Insurance. The publication of the ZIN position on reimbursement under the Basic Insurance Package is scheduled for January 2029.

The project for intranasal mesenchymal stem cells in newborns with hypoxic-ischemic brain damage (iSTOP-CP trial) started on October 01, 2024, and will last for six years. After the completion of the project, the research results will be submitted to ZIN around October 2031 for the decision about inclusion in Basic Health Insurance. The publication of the ZIN position on reimbursement under the Basic Insurance Package is scheduled for April 2032.

See more information in Dutch here.

This news is just one of about 300 market access news collected by our team in the premium subscription service Market Access Monitor every week from more than 80 organizations. Access our paid service to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news). Access is organized as an online Database and email alert formats. Contact us to get a free, three-month, no-obligation trial.